HRQoL was assessed with the Pediatric Quality of Life Inventory (PedsQL)
Primary indication is diabetes management based on blood glucose criteria, not BMI
Heres what early studies have shown: Pancreatitis: Reported in about 0.4% Gallbladder problems: Seen in about 1.1% , with no cases in the placebo group Heart rhythm changes: Reported more often with retatrutide ( about 6% vs 3% with placebo ) Liver enzyme increases: Rare (around 1% ), with overall liver health markers staying stable While these serious side effects were uncommon, theyre still important to keep in mind
Microdose GLP-1 protocols are designed to be gentler, and some patients may find them easier to tolerate
Retatrutide represents the next evolution in metabolic treatment, offering what scientists describe as a triple-action approach that could potentially deliver even more impressive results than current medications
Tirzepatide is a single molecule that activates both the GIP and GLP-1 receptors